{"id":"https://openalex.org/W2012184890","doi":"https://doi.org/10.1007/s00280-005-1022-3","title":"Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft","display_name":"Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft","publication_year":2005,"publication_date":"2005-06-09","ids":{"openalex":"https://openalex.org/W2012184890","doi":"https://doi.org/10.1007/s00280-005-1022-3","mag":"2012184890","pmid":"https://pubmed.ncbi.nlm.nih.gov/15947929"},"language":"en","primary_location":{"id":"doi:10.1007/s00280-005-1022-3","doi":"https://doi.org/10.1007/s00280-005-1022-3","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s00280-005-1022-3","pdf_url":null,"source":{"id":"https://openalex.org/S117498271","display_name":"Cancer Chemotherapy and Pharmacology","issn_l":"0344-5704","issn":["0344-5704","1432-0843"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemotherapy and Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5088868208","display_name":"Feng Luo","orcid":"https://orcid.org/0000-0001-5619-958X","observed_orcids":["https://orcid.org/0000-0001-5619-958X"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"F. R. Luo","raw_affiliation_strings":["Pharmaceutical Research Institute, Oncology Drug Discovery, Bristol-Myers Squibb Company, Princeton, NJ 08543, USA. roger.luo@bms.com","Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, Princeton, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Research Institute, Oncology Drug Discovery, Bristol-Myers Squibb Company, Princeton, NJ 08543, USA. roger.luo@bms.com","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, Princeton, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024512077","display_name":"Zheng Yang","orcid":"https://orcid.org/0000-0002-6044-3298","observed_orcids":["https://orcid.org/0000-0002-6044-3298"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Z. Yang","raw_affiliation_strings":["Pharmaceutical Research Institute, Preclinical Candidate Optimization, Bristol-Myers Squibb Company, 4000, Princeton, NJ, USA","Pharmaceutical Research Institute, Preclinical Candidate Optimization, Bristol-Myers Squibb Company, Princeton, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Research Institute, Preclinical Candidate Optimization, Bristol-Myers Squibb Company, 4000, Princeton, NJ, USA","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"Pharmaceutical Research Institute, Preclinical Candidate Optimization, Bristol-Myers Squibb Company, Princeton, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048686196","display_name":"Huijing Dong","orcid":"https://orcid.org/0000-0003-1563-7816","observed_orcids":["https://orcid.org/0000-0003-1563-7816"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"H. Dong","raw_affiliation_strings":["Pharmaceutical Research Institute, Clinical Discovery Analytical Sciences, Bristol-Myers Squibb Company, New Brunswick, NJ, USA","Pharmaceutical Research Institute, Clinical Discovery Analytical Sciences, Bristol-Myers Squibb Company, New Brunswick, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Research Institute, Clinical Discovery Analytical Sciences, Bristol-Myers Squibb Company, New Brunswick, NJ, USA","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"Pharmaceutical Research Institute, Clinical Discovery Analytical Sciences, Bristol-Myers Squibb Company, New Brunswick, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083967440","display_name":"Amy Camuso","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. Camuso","raw_affiliation_strings":["Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, 4000, Princeton, NJ, 08543, USA","Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, Princeton, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, 4000, Princeton, NJ, 08543, USA","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, Princeton, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027215276","display_name":"Kelly McGlinchey","orcid":"https://orcid.org/0000-0002-4969-5523","observed_orcids":["https://orcid.org/0000-0002-4969-5523"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"K. McGlinchey","raw_affiliation_strings":["Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, 4000, Princeton, NJ, 08543, USA","Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, Princeton, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, 4000, Princeton, NJ, 08543, USA","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, Princeton, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051367332","display_name":"Krista Fager","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"K. Fager","raw_affiliation_strings":["Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, 4000, Princeton, NJ, 08543, USA","Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, Princeton, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, 4000, Princeton, NJ, 08543, USA","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, Princeton, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055799863","display_name":"Christine Flefleh","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. Flefleh","raw_affiliation_strings":["Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, 4000, Princeton, NJ, 08543, USA","Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, Princeton, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, 4000, Princeton, NJ, 08543, USA","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, Princeton, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084542555","display_name":"David Kan","orcid":"https://orcid.org/0009-0008-0636-3124","observed_orcids":["https://orcid.org/0009-0008-0636-3124"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. Kan","raw_affiliation_strings":["Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, 4000, Princeton, NJ, 08543, USA","Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, Princeton, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, 4000, Princeton, NJ, 08543, USA","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, Princeton, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003411418","display_name":"Ivan V. Inigo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"I. Inigo","raw_affiliation_strings":["Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, 4000, Princeton, NJ, 08543, USA","Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, Princeton, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, 4000, Princeton, NJ, 08543, USA","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, Princeton, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086417693","display_name":"Stephen Castaneda","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Castaneda","raw_affiliation_strings":["Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, 4000, Princeton, NJ, 08543, USA","Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, Princeton, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, 4000, Princeton, NJ, 08543, USA","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, Princeton, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103002200","display_name":"William C. Rose","orcid":"https://orcid.org/0000-0003-1582-0856","observed_orcids":["https://orcid.org/0000-0003-1582-0856"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"W. C. Rose","raw_affiliation_strings":["Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, 4000, Princeton, NJ, 08543, USA","Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, Princeton, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, 4000, Princeton, NJ, 08543, USA","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, Princeton, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103689329","display_name":"Robert A. Kramer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. A. Kramer","raw_affiliation_strings":["Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, 4000, Princeton, NJ, 08543, USA","Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, Princeton, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, 4000, Princeton, NJ, 08543, USA","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, Princeton, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038223232","display_name":"Robert A. Wild","orcid":"https://orcid.org/0000-0002-1298-265X","observed_orcids":["https://orcid.org/0000-0002-1298-265X"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. Wild","raw_affiliation_strings":["Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, 4000, Princeton, NJ, 08543, USA","Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, Princeton, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, 4000, Princeton, NJ, 08543, USA","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, Princeton, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5086704967","display_name":"Francis Y. Lee","orcid":"https://orcid.org/0000-0003-2275-2441","observed_orcids":["https://orcid.org/0000-0003-2275-2441"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"F. Y. Lee","raw_affiliation_strings":["Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, 4000, Princeton, NJ, 08543, USA","Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, Princeton, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, 4000, Princeton, NJ, 08543, USA","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"Pharmaceutical Research Institute, Oncology Drug Discovery, Mailstop: K23-03, Bristol-Myers Squibb Company, Princeton, USA","institution_ids":["https://openalex.org/I4210091812"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5088868208"],"corresponding_institution_ids":["https://openalex.org/I4210091812"],"apc_list":{"value":4390,"currency":"USD","value_usd":4390},"apc_paid":null,"fwci":2.0691,"has_fulltext":false,"cited_by_count":84,"citation_normalized_percentile":{"value":0.86424182,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":90,"max":98},"biblio":{"volume":"56","issue":"5","first_page":"455","last_page":"464"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.6958000063896179,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.6958000063896179,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.14010000228881836,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.11980000138282776,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cetuximab","display_name":"cetuximab","score":0.9789999723434448},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9950000047683716},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.8090000152587891},{"id":"https://openalex.org/keywords/epidermal-growth-factor-receptor","display_name":"epidermal growth factor receptor","score":0.8769999742507935},{"id":"https://openalex.org/keywords/colon-cancer","display_name":"colon cancer","score":0.7860000133514404},{"id":"https://openalex.org/keywords/nude-mice","display_name":"nude mice","score":0.9300000071525574},{"id":"https://openalex.org/keywords/plasma-drug-concentration","display_name":"plasma drug concentration","score":0.6470000147819519},{"id":"https://openalex.org/keywords/tumor-drug-concentration","display_name":"tumor drug concentration","score":0.5649999976158142},{"id":"https://openalex.org/keywords/dose-response-relationship","display_name":"dose-response relationship","score":0.578000009059906},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.6800000071525574},{"id":"https://openalex.org/keywords/tumor-growth-inhibition","display_name":"tumor growth inhibition","score":0.699999988079071},{"id":"https://openalex.org/keywords/intraperitoneal-administration","display_name":"intraperitoneal administration","score":0.7919999957084656},{"id":"https://openalex.org/keywords/intravenous-bolus","display_name":"intravenous bolus","score":0.7080000042915344}],"concepts":[{"id":"https://openalex.org/C2779998722","wikidata":"https://www.wikidata.org/wiki/Q420296","display_name":"Cetuximab","level":4,"score":0.8331248760223389},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7710691690444946},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4854498505592346},{"id":"https://openalex.org/C2777546739","wikidata":"https://www.wikidata.org/wiki/Q33525","display_name":"Carcinoma","level":2,"score":0.4730626344680786},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.46244603395462036},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.4555985629558563},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4366823434829712},{"id":"https://openalex.org/C2780278673","wikidata":"https://www.wikidata.org/wiki/Q476743","display_name":"Nude mouse","level":3,"score":0.4174203872680664},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4127485752105713},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.23396897315979004}],"mesh":[{"descriptor_ui":"D000068818","descriptor_name":"Cetuximab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D002277","descriptor_name":"Carcinoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D002277","descriptor_name":"Carcinoma","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D002277","descriptor_name":"Carcinoma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D003110","descriptor_name":"Colonic Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D003110","descriptor_name":"Colonic Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D003110","descriptor_name":"Colonic Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008819","descriptor_name":"Mice, Nude","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047368","descriptor_name":"Tumor Burden","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1007/s00280-005-1022-3","doi":"https://doi.org/10.1007/s00280-005-1022-3","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s00280-005-1022-3","pdf_url":null,"source":{"id":"https://openalex.org/S117498271","display_name":"Cancer Chemotherapy and Pharmacology","issn_l":"0344-5704","issn":["0344-5704","1432-0843"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemotherapy and Pharmacology","raw_type":"journal-article"},{"id":"pmid:15947929","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15947929","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer chemotherapy and pharmacology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9789000153541565,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":38,"referenced_works":["https://openalex.org/W1233276","https://openalex.org/W26155307","https://openalex.org/W135877420","https://openalex.org/W173357120","https://openalex.org/W1554880727","https://openalex.org/W1569865130","https://openalex.org/W1570686199","https://openalex.org/W1939364580","https://openalex.org/W1967457822","https://openalex.org/W1972004339","https://openalex.org/W1983104536","https://openalex.org/W1996469277","https://openalex.org/W1999970132","https://openalex.org/W2001453148","https://openalex.org/W2010174111","https://openalex.org/W2034185792","https://openalex.org/W2049613194","https://openalex.org/W2055903396","https://openalex.org/W2057458801","https://openalex.org/W2082297472","https://openalex.org/W2088597803","https://openalex.org/W2088658971","https://openalex.org/W2100960099","https://openalex.org/W2106764013","https://openalex.org/W2109960839","https://openalex.org/W2116175718","https://openalex.org/W2126055089","https://openalex.org/W2135836172","https://openalex.org/W2142889189","https://openalex.org/W2146447599","https://openalex.org/W2159227997","https://openalex.org/W2159506251","https://openalex.org/W2167531081","https://openalex.org/W2170517479","https://openalex.org/W2171685800","https://openalex.org/W2415032506","https://openalex.org/W2731594918","https://openalex.org/W4244120980"],"related_works":["https://openalex.org/W2103962487","https://openalex.org/W2245844780","https://openalex.org/W2266631974","https://openalex.org/W2018048717","https://openalex.org/W2051084702","https://openalex.org/W2161482321","https://openalex.org/W2531365686","https://openalex.org/W7158088305","https://openalex.org/W1976931620","https://openalex.org/W3201757330"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":1},{"year":2023,"cited_by_count":6},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":5},{"year":2013,"cited_by_count":2},{"year":2012,"cited_by_count":5}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}